Innovative Biotech Solutions

Palena Therapeutics Inc is pleased to announce that Dr. Masha Fridkis-Hareli will be speaking at the 4th Precision Medicine in Inflammatory Bowel Disease Summit next month on March 31- April 2 in Boston, MA! She will be presenting on “Reprogramming Protein Therapeutics to Restore Immune Balance in Animal Models”. 

Learn more about the conference here: https://ter.li/53p4m1 

Worcester, MA, April 16, 2025 – PalenaTherapeutics Inc, developer of novel autoimmune disease therapeutics, has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $305,000 to conduct research and development (R&D) work on its novel immunomodulatoryrandom copolymers, termed Embedded Epitope Random Peptides (EERPs). The grant is focused on using Palena’snovel technology to develop therapeutics for the treatment of juvenile idiopathic arthritis-associated uveitis and pediatric Crohn’sdisease. The Company’s immunomodulatorypeptides represent a new approach for the treatment of autoimmune diseases by reprogramming and not interfering with the function of the immune system to stop disease progression and inflammation which will allow it to function normally to fight infectious diseases. To learn more visit: https://seedfund.nsf.gov/awardees/phase-1/details/?company=palena-therapeutics-inc

Poster at the 2025 IRSF Rett Syndrome Scientific Meeting, Boston, MA, June 9-11, 2025.

Fridkis-Hareli, M. & DiTullio, P.    Novel Neuroprotective Peptide for the Treatment of Rett Syndrome.

Poster at the 2024 IRSF Rett Syndrome Scientific Meeting, Westminster, CO, June 18-19, 2024.

Fridkis-Hareli, M. & DiTullio, P.  Embedded Epitope Random Peptides as Candidate Therapy for Rett Syndrome.

Poster at the 2023 IRSF Rett Syndrome Scientific Meeting, Nashville, TN, June 5-7, 2023.

Fridkis-Hareli, M. & DiTullio, P.  Embedded Epitope Random Peptides as Candidate Therapy for Rett Syndrome.

https://www.flickr.com/photos/197165270@N04/sets/72177720309081197/